Showing posts with the label Takeda
View all

Crescendo Biologics Expands its Ongoing Collaboration with Takeda

IndustryPRwire -- Crescendo Biologics announced that it has expanded its global, multi-target discovery and development collaboration with Takeda Pharmaceutical Company Limited (Takeda) after Crescen…

Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) for the Treatment of Unresectable Hepatocellular Carcinoma That Has Progressed After Prior Systemic Therapy

IndustryPRwire -- Exelixis announced that Takeda Pharmaceutical, its partner responsible for the clinical development and commercialization of CABOMETYX® (cabozantinib) in Japan, received approval f…

Moderna Partners with Takeda and the Government of Japan to Supply 50 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273) to Japan

Moderna confirmed that the Ministry of Health, Labour and Welfare of Japan (MHLW) and Takeda Pharmaceutical Co., Ltd have agreed to purchase and distribute 50 million doses of mRNA-1273, Moderna’s v…

Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable, Advanced or Metastatic Renal Cell Carcinoma in Japan

Exelixis today announced that Takeda Pharmaceutical, its partner responsible for the clinical development and commercialization of CABOMETYX® (cabozantinib) in Japan, and Ono Pharmaceutical Co., Ltd…

HemoShear Therapeutics Enters into Rare Liver Disease Research Collaboration with Takeda

HemoShear Therapeutics has entered into a research collaboration and service agreement with Takeda Pharmaceutical Company Limited ('Takeda"). Under the terms of the agreement, HemoShear wil…
Subscribe Our Newsletter